IMB Dx, Inc. products

AlphaLiquid® Screening is a blood-based test for early detection of multiple cancers. With 10mL of blood, the test analyzes genetic and epigenetic features in cfDNA to screen for signals of cancer as well as predict the tissue of origin.

AlphaLiquid® Detect is an industry-first tumor-informed, hybrid-capture NGS-based liquid biopsy test designed for MRD detection and recurrence monitoring in stage I-III solid tumor patients. The assay incorporates a personalized panel of up to 1,000 targets, including both tumor-informed patient-specific markers as well as additional therapeutic targets. By delivering exceptional detection levels (<0.005% LOD), AlphaLiquid® Detect provides clinically actionable information for relapse monitoring and adjuvant therapy guidance with a significant lead time over conventional imaging diagnostics.